HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor.

Abstract
We have discovered a new, potent, selective, and orally active oxytocin receptor antagonist, (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide (compound 1). We report the biochemical, pharmacological, and pharmacokinetic characterization in vitro and in vivo of this compound. Compound 1 competitively inhibits binding of [3H]oxytocin and the peptide antagonist 125I-ornithine vasotocin analog to human and rat oxytocin receptor expressed in human embryonic kidney 293-EBNA or Chinese hamster ovary cells with nanomolar potency. Selectivity against vasopressin receptor subtypes is >6-fold for V1a and >350-fold for V2 and V1b. Compound 1 inhibits oxytocin-evoked intracellular Ca2+ mobilization (IC50 = 8 nM). Compound 1 has no intrinsic agonist activity at the oxytocin receptor. Oxytocininduced contraction of isolated rat uterine strips is blocked by compound 1 (pA2 = 7.82). In anesthetized nonpregnant rats, single administration of compound 1 by i.v. or oral routes causes dose-dependent inhibition of contractions elicited by repeated injections of oxytocin with ED50 = 3.5 mg/kg i.v. and 89 mg/kg p.o., respectively. Compound 1 significantly inhibits spontaneous uterine contractions in pregnant rats near term when administered intravenously or orally. We conclude that compound 1 is a potent, selective, and orally active nonpeptide oxytocin receptor antagonist, which is a suitable candidate for evaluation as a potential tocolytic agent for the management of preterm labor.
AuthorsRocco Cirillo, Enrico Gillio Tos, Matthias K Schwarz, Anna Quattropani, Alexander Scheer, Marc Missotten, Jerome Dorbais, Anthony Nichols, Francesco Borrelli, Claudio Giachetti, Lucia Golzio, Paolo Marinelli, Russell J Thomas, Claude Chevillard, Florence Laurent, Karine Portet, Claude Barberis, Andre Chollet
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 306 Issue 1 Pg. 253-61 (Jul 2003) ISSN: 0022-3565 [Print] United States
PMID12660315 (Publication Type: Journal Article)
Chemical References
  • Imines
  • N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-1-((2'-methyl(1,1'-biphenyl)-4-yl)carbonyl)-2-pyrrolidinecarboxamide
  • Pyrrolidines
  • Receptors, Oxytocin
  • Receptors, Vasopressin
  • Oxytocin
  • Dinoprost
Topics
  • Anesthesia
  • Animals
  • CHO Cells
  • Cells, Cultured
  • Cricetinae
  • Dinoprost (pharmacology)
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Imines (pharmacology)
  • Oxytocin (pharmacology)
  • Pregnancy
  • Pyrrolidines (pharmacology)
  • Rats
  • Rats, Sprague-Dawley
  • Rats, Wistar
  • Receptors, Oxytocin (antagonists & inhibitors)
  • Receptors, Vasopressin (metabolism)
  • Uterine Contraction (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: